• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Merus N.V.

    11/14/24 6:27:51 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC 13G 1 p24-3252sc13g.htm MERUS N.V.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Merus N.V.

    (Name of Issuer)
     

    Common Shares, nominal value €0.09 per share

    (Title of Class of Securities)
     

    N5749R100

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. N5749R10013GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    4,169,393 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    4,169,393 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,169,393 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. N5749R10013GPage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    4,169,393 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    4,169,393 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,169,393 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. N5749R10013GPage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Merus N.V. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at Uppsalalaan 17, 3584 CT Utrecht, The Netherlands.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:

     

      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Shares, nominal value €0.09 per share (the "Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      N5749R100

     

    CUSIP No. N5749R10013GPage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:_______________________________________________________

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 68,210,479 Shares outstanding as of July 25, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    CUSIP No. N5749R10013GPage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. N5749R10013GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

    RTW INVESTMENTS, LP
       
       
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
       
       
       
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  

     

     

    Get the next $MRUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Merus with a new price target

      Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

      2/13/25 8:09:56 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Merus with a new price target

      Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

      2/7/25 8:26:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Merus with a new price target

      Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

      11/21/24 7:35:31 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO & PEO Lundberg Sven Ante exercised 30,297 shares at a strike of $13.40 (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      4/21/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 3,000 shares and sold $193,990 worth of shares (4,000 units at $48.50), decreasing direct ownership by 8% to 11,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:10:05 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 5,000 shares, increasing direct ownership by 71% to 12,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

      7/1/24 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

      6/15/23 7:47:06 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 4:05:20 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 1:34:01 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 8:54:46 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 6, 2024 - FDA Roundup: December 6, 2024

      For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

      12/6/24 3:09:02 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merus to Present at BofA Securities 2025 Health Care Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About MerusMerus is an oncology company de

      5/8/25 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Financials

    Live finance-specific insights

    See more
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

      -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

      2/27/25 4:10:40 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merus N.V.

      10-Q - Merus N.V. (0001651311) (Filer)

      5/7/25 4:05:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Merus N.V.

      DEF 14A - Merus N.V. (0001651311) (Filer)

      4/24/25 4:05:39 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Merus N.V.

      PRE 14A - Merus N.V. (0001651311) (Filer)

      4/14/25 4:15:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care